2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.12D.02 Treatment Strategies and Survival Outcomes of Advanced NSCLC with HER2 Mutation and BM: A Multicenter Retrospective Study

EP.12D.02 Treatment Strategies and Survival Outcomes of Advanced NSCLC with HER2 Mutation and BM: A Multicenter Retrospective Study

Back to course

Pdf Summary

The study investigates the treatment regimens and survival outcomes for patients with advanced non-small cell lung cancer (NSCLC) with HER2 mutations and brain metastases (BM). Conducted at multiple centers, the retrospective study evaluated the clinical outcomes of patients with this particular cancer type, focusing mainly on overall survival (OS). Over a five-year period, 6536 advanced NSCLC patients were screened, and 183 were identified as having HER2 mutations, with 91 of these patients having brain metastases.<br /><br />Key findings include:<br /><br />1. **Incidence**: BM was found in 24.6% of patients at the initial diagnosis of HER2-mutant NSCLC and in 49.7% throughout the disease course.<br /><br />2. **Survival Outcomes**: Patients with BM had a median OS of 14.8 months, significantly less than the 23.2 months for those without BM (p<0.001).<br /><br />3. **Treatment Impact**: <br />   - Antibody-drug conjugates (ADCs) notably improved OS (18.4 months) compared to those who only received tyrosine kinase inhibitors (TKIs) or neither (13.2 and 13.8 months respectively, p=0.008).<br />   - Brain radiotherapy was linked to enhanced survival (16.9 vs. 12.3 months, p<0.001).<br /><br />4. **Predictors of OS**: Multivariate analysis highlighted ADC treatments, brain radiotherapy, Eastern Cooperative Oncology Group Performance Status (ECOG-PS) scores, and BM-related symptoms as independent OS predictors.<br /><br />5. **Treatment Dynamics**: Various treatment regimens, such as chemotherapies, anti-angiogenesis therapies, immunotherapies, and TKIs, show a complex flow among patients, depending on the mutation subtypes and response rates.<br /><br />The study confirms that while the prognosis for NSCLC patients with HER2 mutations and BM is generally poor, treatments with ADCs and brain radiotherapy significantly improve survival outcomes, underscoring the importance of personalized therapy regimens.

Asset Subtitle

Yun Fan

Meta Tag

Speaker Yun Fan

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Keywords

NSCLC

HER2 mutations

brain metastases

overall survival

antibody-drug conjugates

brain radiotherapy

treatment regimens

clinical outcomes

multivariate analysis

personalized therapy